Brokerages Set VolitionRX Limited (NYSEAMERICAN:VNRX) Price Target at $46.67

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $46.6667.

Several equities research analysts recently weighed in on the company. Citigroup cut VolitionRX to a “hold” rating in a report on Monday, April 20th. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. HC Wainwright decreased their target price on VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Finally, Benchmark reissued a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd.

Institutional Trading of VolitionRX

A number of institutional investors and hedge funds have recently modified their holdings of VNRX. Virtu Financial LLC purchased a new position in shares of VolitionRX in the 3rd quarter worth $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of VolitionRX in the second quarter valued at about $52,000. Jane Street Group LLC purchased a new position in shares of VolitionRX in the fourth quarter valued at about $28,000. Squarepoint Ops LLC purchased a new position in shares of VolitionRX in the fourth quarter valued at about $34,000. Finally, Citadel Advisors LLC increased its holdings in shares of VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the last quarter. Institutional investors own 8.09% of the company’s stock.

VolitionRX Price Performance

Shares of VNRX stock opened at $1.39 on Tuesday. The stock has a market capitalization of $12.00 million, a PE ratio of -0.33 and a beta of 1.04. VolitionRX has a 1-year low of $1.35 and a 1-year high of $18.80. The business has a 50-day moving average of $2.85 and a 200 day moving average of $4.32.

VolitionRX (NYSEAMERICAN:VNRX) last issued its earnings results on Thursday, May 14th. The medical research company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The company had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.52 million. Analysts anticipate that VolitionRX will post -2.4 EPS for the current year.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.